Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

被引：14

作者：

Guisado-Vasco, Pablo

Arranz-Saez, Reyes ^{[2
]}

Canales, Miguel ^{[3
]}

Canovas, Araceli ^{[4
]}

Garcia-Larana, Jose

Garcia-Sanz, Ramon ^{[5
]}

Lopez, Andres ^{[6
]}

Luis Lopez, Jose ^{[7
]}

Llanos, Marta ^{[8
]}

Maria Moraleda, Jose ^{[9
]}

Rodriguez, Jose ^{[10
]}

Rayon, Consuelo ^{[13
]}

Sabin, Pilar ^{[11
]}

Salar, Antonio ^{[12
]}

Marin-Niebla, Ana ^{[14
]}

Morente, Manuel ^{[15
]}

Sanchez-Godoy, Pedro ^{[16
]}

Francisco Tomas, Jose ^{[17
]}

Muriel, Alfonso ^{[18
]}

Abraira, Victor ^{[18
]}

Piris, Miguel A. ^{[19
]}

Garcia, Juan F. ^{[15
]}

Montalban, Carlos ^{[1
]}

机构：

[1] Hosp Ramon & Cajal, Med Interna Serv, E-28034 Madrid, Spain

[2] Hosp La Princesa, Madrid, Spain

[3] Hosp La Paz, Madrid, Spain

[4] Hosp Cruces, Bilbao, Spain

[5] Hosp Univ Salamanca, Salamanca, Spain

[6] Hosp Valle De Hebron, Barcelona, Spain

[7] Fdn Jimenez Diaz, E-28040 Madrid, Spain

[8] Hosp Univ Canarias, Tenerife, Spain

[9] Hosp Univ Virgen de la Arrixaca, Murcia, Spain

[10] Hosp Son Dureta, Palma De Mallorca, Spain

[11] Hosp Gen Gregorio Maranon, Madrid, Spain

[12] Hosp del Mar, Barcelona, Spain

[13] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain

[14] Hosp Virgen del Rocio, Seville, Spain

[15] CNIO, Mol Pathol Programme, Madrid, Spain

[16] Hosp Severo Ochoa, Madrid, Spain

[17] MD Anderson Espana, Madrid, Spain

[18] CIBERESP, IRYCIS, Madrid, Spain

[19] Hosp Marques de Valdecilla, Santander, Spain

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 05期

关键词：

Hodgkin lymphoma; International Prognosis Score (IPS); outcome prediction; REGULATORY T-CELLS; DISEASE; MACROPHAGES; SURVIVAL;

D O I：

10.3109/10428194.2011.635861

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The International Prognostic Score (IPS) is the most widely used system to date for identifying risk groups for the outcome of patients with advanced Hodgkin lymphoma, although important limitations have been recognized. We analyzed the value of the IPS in a series of 311 patients with advanced classical Hodgkin lymphoma (cHL) (Ann Arbor stage III, IV or stage II with B symptoms and/or bulky masses) treated with first-line chemotherapy including adriamycin (adriamycin, bleomycin, vinblastine, dacarbazine [ ABVD] or equivalent variants). In univariate and multivariate analyses, stage IV disease and age >= 45 years were the only factors with independent predictive significance for overall survival (OS) (p = 0.002 and p < 0.001, respectively). Stage IV was still significant for freedom from progression (FFP) (p = 0.001) and age >= 45 years was borderline significant (p = 0.058). IPS separates prognostic groups, as in the original publication, but this is mainly due to the high statistical significance of stage IV and age >= 45 years. Moreover, the combination of these two factors enables a simpler system to be constructed that separates groups with different FFP and OS. In conclusion, in our series, stage IV and age >= 45 years are the key prognostic factors for the outcome of advanced cHL.

引用

页码：812 / 819

页数：8

共 15 条

[1] Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].